Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12813692 | 0.86 | KDM1A (0.57) | GAAMAOBMEN1KMT2A | |
| SCHEMBL29038989 | 0.85 | HRH3 (0.53) | GAAMAOB | |
| SCHEMBL4261542 | 0.84 | GAA (0.66) | GAAMAOBMEN1KMT2A | |
| SCHEMBL4259748 | 0.84 | GAA (0.66) | GAAMAOBMEN1KMT2A | |
| SCHEMBL4267783 | 0.84 | GAA (0.66) | GAAMAOBMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL30468821 | 0.84 | HRH3 (0.53) | GAAMAOB | |
| SCHEMBL4267387 | 0.83 | GAA (0.64) | GAAMAOBMEN1KMT2A | |
| SCHEMBL20527292 | 0.83 | GAA (0.64) | GAAMAOBMEN1KMT2A | |
| SCHEMBL6153849 | 0.83 | GAA (1.00) | GAAMEN1KMT2A | |
| SCHEMBL4264868 | 0.83 | CYP2D6 (0.64) | GAAMAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | claimed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | claimed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | claimed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | claimed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | claimed |
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | CONNOLLY PETER J | 2008-12-04 | — | — | US | disclosed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | disclosed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | disclosed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | disclosed |
| WO-2007092879-A2 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2006118749-A1 | THIA-TETRAAZAACENAPHTHYLENE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | GAA 2069/4885MAOB 2310/4885MEN1 2186/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | GAA 679/4885MAOB 2142/4885MEN1 4404/4885 |
| US-20080300264-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | GAA 2069/4885MAOB 2310/4885MEN1 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.